文献速递中医内科中药与中成药合理使用

心宝丸抗慢性心力衰竭活性成分的化学轮廓、药代动力学与药效学整合研究

Uncovering the active ingredients of Xinbao pill against chronic heart failure: A chemical profiling, pharmacokinetics and pharmacodynamics integrated study.
PubMed 文献 · J Ethnopharmacol · 2025-01-27

该研究在大鼠慢性心力衰竭(CHF)模型中评估心宝丸(XBP)的药效、化学轮廓与药代动力学,发现人参皂苷Rg1、Rg2与三七皂苷R1可能为抗CHF活性成分。三者混合可改善CHF,主要定位于线粒体,通过抑制血红素合成途径减少琥珀酰辅酶A分解以增强线粒体稳态。

要点

  • 心宝丸可改善CHF大鼠心功能、降低NT-pro BNP、减轻心肌损伤并降解细胞外胶原。
  • 人参皂苷Rg1、Rg2与三七皂苷R1混合可产生与心宝丸类似的抗CHF效应。
  • 上述三成分主要定位于线粒体,通过抑制血红素合成途径增强线粒体稳态。

核心结论

  • 人参皂苷Rg1、人参皂苷Rg2与三七皂苷R1可能是心宝丸抗慢性心力衰竭的活性成分。
  • 这些成分通过抑制血红素合成以增加琥珀酰辅酶A,促进线粒体稳态。

研究设计与样本

  • 在慢性心力衰竭模型大鼠中评估心宝丸的药效、化学轮廓与药代动力学。
  • 采用靶向代谢组学与蛋白质印迹分析阐明可能活性成分混合物的抗CHF机制。

主要发现

  • 心宝丸通过增强心功能、降低NT-pro BNP、减轻心肌损伤和降解细胞外胶原缓解CHF。
  • CHF组中人参皂苷Rg1与三七皂苷R1的AUC0-t呈下降趋势,CL/F呈升高趋势。
  • CHF大鼠心脏中人参皂苷Rg1、人参皂苷Rg2与三七皂苷R1水平显著升高。
  • 三成分混合物改善CHF的效应与心宝丸相似,并主要定位于线粒体。

关键数值与推荐

  • 心宝丸可降低CHF模型大鼠的NT-pro BNP。
  • CHF组人参皂苷Rg1与三七皂苷R1的AUC0-t呈下降趋势、CL/F呈升高趋势。
  • CHF大鼠心脏中人参皂苷Rg1、Rg2与三七皂苷R1水平显著升高。

临床怎么用

  • 心宝丸用于慢性心力衰竭的近30年临床实践获得该研究对其活性成分的机制支持。
  • 人参皂苷Rg1、Rg2与三七皂苷R1可作为心宝丸抗CHF质量标志物的候选成分。

局限性

  • 研究在CHF模型大鼠中进行,结论外推至人体需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Xinbao pill (XBP) is a renowned Chinese patent medicine, primarily efficacious in warming and nourishing the heart and kidneys, supplementing Qi to boost Yang, and promoting blood circulation to remove blood stasis. XBP has been utilized for the treatment of chronic heart failure (CHF) for nearly 30 years, but the lack of clarity regarding the active ingredients of XBP against CHF has hindered its clinical application and further promotion. AIM OF THE STUDY: To comprehensively elucidate the efficacy-specific ingredients and potential mechanism of XBP against CHF. METHODS: The efficacy, chemical profiling and pharmacokinetics of XBP was assessed in a CHF model rat. The anti-CHF mechanism of the mixture of the likely active ingredients was clarified by targeted metabolomics and western blotting analysis. RESULTS: XBP alleviated CHF by enhancing cardiac function, reducing NT-pro BNP, mitigating myocardial damage and degrading extracellular collagen. Following XBP administration, ginsenosides exposed relatively abundant in sham or CHF rats. Ginsenoside Rg1 and notoginsenoside R1 showed downward trends in AUC0-t values in CHF group, accompanied by increasing trends in CL/F values. Moreover, CHF rats presented significantly elevated levels of ginsenoside Rg1, ginsenoside Rg2 and notoginsenoside R1 in heart. The mixture of ginsenoside Rg1, ginsenoside Rg2 and notoginsenoside R1 demonstrated remarkable efficacy in ameliorating CHF as XBP did. Notably, these three compounds were predominantly localized in mitochondria and exhibited significant potential to enhance mitochondrial homeostasis by inhibiting heme synthesis pathway-mediated decomposition of succinyl CoA. CONCLUSIONS: Our research provides valuable insights that ginsenoside Rg1, ginsenoside Rg2 and notoginsenoside R1 may constitute the anti-CHF active ingredients of XBP for facilitating mitochondrial homeostasis by the suppression of heme synthesis to increase succinyl CoA.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Chen W, Luo X, Li W, et al. Uncovering the active ingredients of Xinbao pill against chronic heart failure: A chemical profiling, pharmacokinetics and pharmacodynamics integrated study. J Ethnopharmacol. 2025. PMID: 39880064. doi:10.1016/j.jep.2025.119418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。